BNP Paribas Financial Markets Has $3.78 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

BNP Paribas Financial Markets lifted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 472.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 496,784 shares of the biotechnology company's stock after purchasing an additional 409,938 shares during the quarter. BNP Paribas Financial Markets owned 0.24% of BioCryst Pharmaceuticals worth $3,776,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of BCRX. FMR LLC increased its stake in BioCryst Pharmaceuticals by 2.4% in the third quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company's stock valued at $15,112,000 after acquiring an additional 46,110 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of BioCryst Pharmaceuticals by 40.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company's stock valued at $2,274,000 after purchasing an additional 86,571 shares during the last quarter. Fisher Asset Management LLC raised its holdings in shares of BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock worth $25,369,000 after buying an additional 481,359 shares in the last quarter. Alpha DNA Investment Management LLC bought a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter worth $448,000. Finally, Algert Global LLC lifted its position in shares of BioCryst Pharmaceuticals by 46.2% during the 3rd quarter. Algert Global LLC now owns 516,209 shares of the biotechnology company's stock worth $3,923,000 after buying an additional 163,076 shares during the last quarter. Institutional investors own 85.88% of the company's stock.

Wall Street Analysts Forecast Growth

BCRX has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $14.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Barclays increased their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, BioCryst Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $15.60.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock traded up $0.51 on Thursday, hitting $7.84. The stock had a trading volume of 2,770,546 shares, compared to its average volume of 2,887,087. The stock has a 50 day moving average of $7.58 and a 200 day moving average of $7.33. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $8.88. The firm has a market capitalization of $1.62 billion, a P/E ratio of -12.85 and a beta of 1.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. BioCryst Pharmaceuticals's revenue was up 35.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.19) EPS. Equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.